



- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2024/054285
- (22) **International Filing Date:**
01 November 2024 (01.11.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|--------------------------------|----|
| 63/595,741 | 02 November 2023 (02.11.2023) | US |
| 63/623,768 | 22 January 2024 (22.01.2024) | US |
| 63/643,222 | 06 May 2024 (06.05.2024) | US |
| 63/660,968 | 17 June 2024 (17.06.2024) | US |
| 63/698,944 | 25 September 2024 (25.09.2024) | US |
- (71) **Applicant:** **BE BIOPHARMA, INC.** [US/US]; One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US).
- (72) **Inventors:** **LIU, Hanlan**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **LEACH, Sarah Grace**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **BAIN-**

TER, JR., Wayne; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **CLEMENTS, Madison Ashley**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **MORGAN, Richard A.**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **MULLEN, Timothy James**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **HOHMANN, Anja Fides**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **DASTAGIR, Shamael Rabbia**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **GUJJA, Sharvari**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **KEEGAN, Sean Patrick**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **STANLIE, Andre**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **OHSUMI, Toshiro Kendrick**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **MUSIAL-SIWEK,**

- (54) **Title:** ENGINEERED CELL PREPARATIONS FOR TREATMENT OF HYPOPHOSPHATASIA




FIGURE 1A

- (57) **Abstract:** The present disclosure provides methods and compositions for culturing, engineering, and administering engineered B lineage cell populations that produce an ALP or a fusion protein thereof, such as ALP-Fc fusion protein comprising alkaline phosphatase and human immunoglobulin fragment crystallizable region.

[Continued on next page]

Monika; c/o Be Biopharma, Inc., One Kendall Square,
Building 200, Third Floor, Cambridge, MA 02139 (US).

(74) **Agent: KITTO, Rebekah Z.** et al.; Choate, Hall & Stewart
LLP, Two International Place, Boston, Massachusetts 02110
(US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*